Log in

Relevant bibliographies by topics / Monoclonal therapy / Dissertations / Theses

To see the other types of publications on this topic, follow the link: Monoclonal therapy.

Dissertations / Theses on the topic 'Monoclonal therapy'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 dissertations / theses for your research on the topic 'Monoclonal therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.

1

Coles, A. "Monoclonal antibody therapy of multiple sclerosis." Thesis, University of Cambridge, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.597844.

Full text

Abstract:

T cells mediate the inflammatory activity of multiple sclerosis, which is directed against an unknown autoantigen. A non-antigen specific treatment strategy was tested, drawing on the experimental demonstration of long term allograft acceptance following short term therapy with monoclonal antibodies against T cells. The treatment of 27 patients with multiple sclerosis using a single pulse of humanised anti-lymphocyte (CD52) antibody, Campath-1H, was investigated. With the first dose of monoclonal antibody, patients experienced a rehearsal of previous relapses that fully resolved and was associ

APA, Harvard, Vancouver, ISO, and other styles

2

Hammaker, Deepa Rajan. "Monoclonal antibody therapy of rheumatoid arthritis." Diss., The University of Arizona, 1999. http://hdl.handle.net/10150/289074.

Full text

Abstract:

Objectives. To (a) determine the immunological effects of a PRIMATIZED® anti-CD4 antibody alone or in combination with methotrexate in RA patients, (b) determine the immunological effects of a chimeric anti-CD25 antibody in RA patients who are partially refractive to methotrexate and (c) compare interleukin-15 levels in the serum of RA patients and healthy controls and determine if there is a correlation between this cytokine and serum TNF-α, CD 122 expression, and disease activity. Patients and methods. (a) Eight RA patients were selected, four received anti-CD4+ placebo and the other four re

APA, Harvard, Vancouver, ISO, and other styles

3

Austin, Eric B. "Human monoclonal antibodies." Thesis, University of Nottingham, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.276187.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Kolk, Lizetta Elisabeth van der. "CD20 monoclonal antibody therapy for B-cell lymphoma." [S.l. : Amsterdam : s.n.] ; Universiteit van Amsterdam [Host], 2001. http://dare.uva.nl/document/58282.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Gilliland, Lisa Kim. "The development of bispecific monoclonal antibodies for therapy." Thesis, University of Cambridge, 1987. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.278214.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Conaghan, Philip J. "CEA-targeted monoclonal antibody therapy in colorectal cancer." Thesis, University of Oxford, 2009. http://ora.ox.ac.uk/objects/uuid:149eb061-c563-4e22-9e07-8992b144c0fc.

Full text

Abstract:

Introduction The adjuvant treatment of colorectal cancer (CRC) has seen little improvement in terms of mortality of the disease in the last 40 years. There has been a resurgence in research into the use of monoclonal antibodies in the treatment of CRC. Carcinoembryonic antigen (CEA) is a useful target in cancer immunotherapy. The distribution of CEA in CRC differs from that in normal colorectal tissue. In normal colorectal tissue CEA is found only on the luminal surface of the cell which is inaccessible to intravenous antibody, whereas in CRC, CEA is found on all borders of the cell membrane a

APA, Harvard, Vancouver, ISO, and other styles

7

Nicholson, Stephen. "Immune responses following monoclonal antibody therapy of ovarian cancer." Thesis, Imperial College London, 2000. http://hdl.handle.net/10044/1/8395.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Bindon, Carol Ianthe. "Complement-mediated lysis by monoclonal antibodies for human therapy." Thesis, University of Cambridge, 1987. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.253842.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

James, Marian. "Monoclonal antibody studies of dystrophin and utrophin." Thesis, University of Salford, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.360455.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Sandin, Linda. "Immunomodulatory Therapy of Solid Tumors : With a Focus on Monoclonal Antibodies." Doctoral thesis, Uppsala universitet, Klinisk immunologi, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-210080.

Full text

Abstract:

Cancer, historically considered a genetic disease, is currently acknowledged to affect the whole body. Our immune system is one key player that can elicit a response against malignant cells but can also promote tumorigenesis. Tumors avoid immune recognition by creating a suppressive microenvironment and inducing tolerance. T-cells are regarded a major effector cell type in tumor immunotherapy. An important ”switch” needed for T-cell activation involves so-called costimulatory and coinhibitory receptors. In this thesis, experimental tumor models were used to investigate the potential of immunom

APA, Harvard, Vancouver, ISO, and other styles

11

Osunmuyiwa, Y. "Preparation and characterisation of daunomycin-monoclonal antibody conjugates for cancer therapy." Thesis, University of Nottingham, 1988. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.332619.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Ogunmuyiwa, Y. "Preparation and charecterisation of daunomycin-monoclonal antibody conjugates for cancer therapy." Thesis, University of Nottingham, 1988. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.381443.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Wang, Siao-Yi. "Interactions between complement and cellular mediated mechanisms of monoclonal antibody therapy." Diss., University of Iowa, 2010. https://ir.uiowa.edu/etd/619.

Full text

Abstract:

Monoclonal antibodies (mAbs) have become an important part of therapy for a number of cancers. The first mAb to be approved for clinical use is rituximab, which is currently used for the treatment of various B cell malignancies. Despite its clinical value, the mechanisms in which rituximab induces tumor regression are unclear. Growing evidence suggests that multiple mechanisms involving complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) are involved. However, the direct interactions between CDC and ADCC have yet to be investigated. My studies examine th

APA, Harvard, Vancouver, ISO, and other styles

14

Murray, Samuel. "Monoclonal antibodies in the diagnosis, staging and therapy of Langerhans cell histiocytosis." Thesis, Imperial College London, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.298803.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Hjelm, Skog Anna-Lena. "Monoclonal antibodies and cytokines for therapy of patients with advanced colorectal carcinoma : a clinical and immunological study /." Stockholm, 2000. http://diss.kib.ki.se/2000/91-628-4511-x/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Segerström, Lova Perup. "Novel experimental targeted therapy in neuroblastoma." Stockholm : Department of women's and children's health, Karolinska Institutet, 2009. http://diss.kib.ki.se/2009/978-91-7409-675-0/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Tipton, Thomas R. W. "Understanding the role for Fc gamma receptors in response to anti-CD20 monoclonal antibody therapy." Thesis, University of Southampton, 2015. https://eprints.soton.ac.uk/415837/.

Full text

Abstract:

Research into cancer therapeutics has utilized the antigen specificity of antibodies to provide targeted cancer treatments. One notable therapeutic is rituximab, a chimeric human IgG1 antibody that has specificity to the CD20 protein on the surface of B cells. This antibody is currently used in the treatment of leukaemia and lymphoma. However, due to reasons not fully understood patients often relapse and become resistant to therapy. Therefore an increasingly important area of research is to uncover the key mechanisms of action of anti-CD20 antibodies. It has been demonstrated that antibody Fc

APA, Harvard, Vancouver, ISO, and other styles

18

Lundin, Jeanette. "Targeted CD52 therapy in lymphoid malignancies : a clinical and immunological study /." Stockholm, 2003. http://diss.kib.ki.se/2003/91-7349-441-0/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Song, Emma Yanjun Clinical School St George Hospital Faculty of Medicine UNSW. "Targeted alpha therapy for epithelial ovarian cancer." Awarded by:University of New South Wales. Clinical School - St George Hospital, 2007. http://handle.unsw.edu.au/1959.4/40874.

Full text

Abstract:

Purpose: Control of micrometastatic ovarian cancer in the peritoneal cavity remains a major objective in post-surgical treatment. The purpose of this project was to investigate the efficacy and toxicity of targeted alpha therapy (TAT) for ovarian cancer in vitro and in vivo in animal models and to select the optimal targeting vector for an ovarian cancer clinical trial. Animal models of ovarian, breast and prostate cancer were developed and for further TAT; a phase I melanoma clinical trial was supported, paving the way for an ovarian cancer clinical trial. Methods: The expression of the turn

APA, Harvard, Vancouver, ISO, and other styles

20

Stiff, Andrew Robert. "Enhancing Immune Therapy for Cancer by Targeting Myeloid Derived Suppressor Cells." The Ohio State University, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=osu1494081640848458.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Zhao, Xiaobin. "Targeting CD37 and folate receptor for cancer therapy strategies based on engineered protein and liposomes /." Columbus, Ohio : Ohio State University, 2007. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1174678307.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Zhu, Hui. "The biodistribution of monoclonal antibodies and effector cells : pharmacokinetic modeling and its role in cancer diagnosis and therapy." Thesis, Massachusetts Institute of Technology, 1996. http://hdl.handle.net/1721.1/10311.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Ali, Sumaira. "Development and characterisation of novel monoclonal antibodies against colorectal tumour cells for use in cancer diagnosis and therapy." Thesis, Kingston University, 2013. http://eprints.kingston.ac.uk/40725/.

Full text

Abstract:

Colorectal cancer is a major public health problem and a leading cuase of cancer deaths in the western world. At present, three monoclonal antibodies (mAbs) namely anti-epidermal growth factor receptor (EGFR) cetuximab and panitumumab and anti-vascular endothelial growth factor mAb bevacizumab have been approved for the treatment of patients with metastatic colorectal cancer. However, many patients simply do not respond, or the cancer aquires resistance following a short course of therapy. The aim of this study was to develop a new panel of mouse monoclonal antibodies directed against other ce

APA, Harvard, Vancouver, ISO, and other styles

24

Wareham, Carol. "Exploring the efficacy of anti-GD2 and anti-4-1BB monoclonal antibody therapy for the treatment of neuroblastoma." Thesis, University of Southampton, 2014. https://eprints.soton.ac.uk/376894/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Marcelino, Eduardo Miguel Baptista Ferreira. "Protein disulfide isomerase as a target for besnoitiosis therapy : molecular characterization and studies of its role in infection and host immune response." Doctoral thesis, Universidade de Lisboa. Faculdade de Medicina Veterinária, 2016. http://hdl.handle.net/10400.5/11693.

Full text

Abstract:

Tese de Doutoramento em Ciências Veterinárias na especialidade de Sanidade Animal<br>amedmarcelino@fmv.ulisboa.pt<br>Besnoitia besnoiti is an apicomplexan parasite responsible for bovine besnoitiosis, a disease with a high prevalence in tropical and subtropical regions and re-emerging in Europe. Despite the great economical losses associated with besnoitiosis, this disease has been underestimated and poorly studied, and neither an effective therapy nor a vaccine to be used in Europe is available. Protein disulfide isomerase (PDI) is an essential enzyme for the acquisition of the correct three-

APA, Harvard, Vancouver, ISO, and other styles

26

Clayton, Lisa Victoria Jane Eynstone. "Generation and characterisation of anti-C6 monoclonal antibodies in C6-deficient mice : the search for an anti-C6 therapy." Thesis, Cardiff University, 2006. http://orca.cf.ac.uk/54080/.

Full text

Abstract:

For the second approach, monoclonal antibodies were raised against rabbit, rat, mouse and human C6. The two most interesting antibodies were raised against human C6 and inhibited complement-mediated haemolysis in a cell-based assay. Both of these antibodies were species specific, excluding the possibility of testing their therapeutic properties in animal models of complement-mediated disease. Instead, an ex vivo model of cardiopulmonary bypass was established and used to test the ability of these antibodies to block soluble C5b-9 formation. Neither antibody inhibited soluble C5b-9 formation, s

APA, Harvard, Vancouver, ISO, and other styles

27

Dalmases, Massegú Alba 1982. "Acquired resistance to the anti-EFGR monoclonal antibody cetuximab in colorectal cancer." Doctoral thesis, Universitat Pompeu Fabra, 2012. http://hdl.handle.net/10803/84183.

Full text

Abstract:

EGFR is a transmembrane tyrosine kinase receptor from the HER family which, upon ligand stimulation, activates different signaling pathways involved in tumorogenesis. EGFR can be targeted by monoclonal antibodies, as cetuximab and panitumumab, which bind to EGFR preventing ligand stimulation of the receptor. Cetuximab and panitumumab are approved for colorectal cancer treatment. However, its clinical success is uniformily limited by the development of acquired drug resistance. We describe a new mechanism of acquired resistance to cetuximab in colorectal cancer that was due to a missense mu

APA, Harvard, Vancouver, ISO, and other styles

28

Junker, Markus [Verfasser], and Roland [Gutachter] Benz. "Development and characterization of monoclonal antibodies to GDF-15 for potential use in cancer therapy / Markus Junker. Gutachter: Roland Benz." Würzburg : Universität Würzburg, 2016. http://d-nb.info/1111888531/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Cherradi, Sara. "Les claudines dans le cancer colorectal : ciblage thérapeutique de la claudine-1." Thesis, Montpellier, 2018. http://www.theses.fr/2018MONTT082.

Full text

Abstract:

En France, le cancer colorectal (CCR) est la 2ème cause de décès par cancer. Chez les patients, lorsque la tumeur est localisée, elle est réséquée par chirurgie. Toutefois, 50% des patients sont diagnostiqués à un stade métastatique, ces patients sont alors traités par chimiothérapie (FOLFOX/FOLFIRI), souvent en combinaison avec des thérapies ciblées incluant des anticorps tel que le Cetuximab (anti-EGFR) ou le Bevacizumab (anti-VEGF). Cependant, il reste encore environ 40% des patients qui ne répondent pas au traitement et l’une des causes les mieux établies est l'influence des mutations de l

APA, Harvard, Vancouver, ISO, and other styles

30

Guardia, Valenzuela Cristina 1990. "Cancer-associated fibroblasts and response to anti-HER2 monoclonal antibodies in breast cancer." Doctoral thesis, Universitat Pompeu Fabra, 2019. http://hdl.handle.net/10803/668327.

Full text

Abstract:

El cáncer de mama HER2-positivo es un subtipo muy agresivo. El desarrollo de terapias anti-diana HER2, particularmente el anticuerpo monoclonal (Mab) trastuzumab, supuso una mejora significativa en el pronóstico de esta enfermedad. De manera más reciente, otro Mab llamado pertuzumab, ha mejorado todavía más la eficiencia de trastuzumab. Aún y así, no todas las pacientes se beneficiarán de esta combinación de mAbs. Una proporción de estas pacientes no se beneficiarán de estas terapias anti-HER2, y fallecerán a causa de la presencia o el desarrollo de mecanismos de resistencia. Los tumores con

APA, Harvard, Vancouver, ISO, and other styles

31

Ortigosa, Luciena Cegatto Martins. "Avaliação da resposta imune anti-Mycobacterium tuberculosis em pacientes com psoríase moderada a grave submetidos à terapia com inibidor de fator de necrose tumoral, infliximabe." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/5/5133/tde-06082014-103109/.

Full text

Abstract:

O tratamento de pacientes apresentando doenças inflamatórias imunomediadas com drogas anti-TNF-alfa aumenta o risco da reativação da tuberculose. Isso sugere que tais drogas possam afetar a imunidade celular destes. No entanto, há dados conflitantes sobre se esse tratamento suprime as respostas para o teste tuberculínico (TT) e os ensaios de liberação de interferon-gama (IGRAs) e poucos dados em pacientes com psoríase. O presente estudo avaliou pacientes com psoríase moderada a grave enfocando os efeitos do tratamento com infliximabe em suas respostas imunológicas celulares. Foram avaliadas as

APA, Harvard, Vancouver, ISO, and other styles

32

Silva, Pedro José Flores Vieira e. "Parâmetros associados a sibilância recorrente após bronquite aguda." Doctoral thesis, Faculdade de Ciências Médicas. Universidade Nova de Lisboa, 2008. http://hdl.handle.net/10362/5200.

Full text

Abstract:

RESUMO Introdução: a bronquiolite aguda afecta 30 a 60% das crianças saudáveis até ao terceiro aniversário. Destas, 50% evoluem para sibilância recorrente, com consequências pessoais, familiares e sociais relevantes. Objectivos: identificação de parâmetros clínicos e laboratoriais associados à sibilância recorrente em crianças saudáveis. A detecção da actividade local de quatro citocinas intervenientes nas vias imunológicas Th1 ou Th2 permitiu, gualmente, o estudo do respectivo comportamento em função dos referidos parâmetros. Material e Métodos: estudo prospectivo de coorte, efectuado no

APA, Harvard, Vancouver, ISO, and other styles

33

Rahal, Amal. "Anti-idiotypic induction therapy for the treatment of chronic inflammatory disorders. Therapeutic evaluation of two anti-SLE A monoclonal antibodies in an animal model for acute inflammation." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape9/PQDD_0017/MQ47086.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Malheiros, Anna Paula Rocha. "Resultado do tratamento da doença de Crohn com anti-fator de necrose tumoral alfa." Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/5/5154/tde-05112008-135045/.

Full text

Abstract:

A doença de Crohn é uma inflamação crônica do trato gastrointestinal. O tratamento convencional é muitas vezes desapontador. Apesar da variedade de drogas disponíveis para o tratamento da doença inflamatória intestinal, tais como: salicilatos e seus derivados, corticosteróides, antibióticos e imunossupressores, nenhuma destas mostrou ser totalmente eficaz ou definitiva para o tratamento da doença e seus surtos de exacerbação. Pesquisas têm sido desenvolvidas com o objetivo de apresentar drogas mais efetivas. Dentre estas, destacam-se as drogas biológicas. O infliximabe é um anticorpo monoclona

APA, Harvard, Vancouver, ISO, and other styles

35

Gramann, Alec K. "The Role of BMP Signaling in the Melanocyte Lineage and as a Therapeutic Target in Melanoma." eScholarship@UMMS, 2020. https://escholarship.umassmed.edu/gsbs_diss/1066.

Full text

Abstract:

Melanoma is one of the most aggressive and deadly forms of skin cancer. Arising from melanocytes, a pigment cell population derived from the neural crest, melanomas often adopt characteristics associated with the neural crest – the ability to rapidly proliferate, migrate and invade throughout the body. Historically, these characteristics along with a baseline resistance to chemotherapy have made melanoma extremely difficult to treat. Improvements in targeted and immunotherapeutic options have improved patient outcomes, but many patients still experience limited durable responses to therapy. In

APA, Harvard, Vancouver, ISO, and other styles

36

Akramienė, Dalia. "Assessment of the modulation of photodynamic effect by β-glucan and characteristics of anti-CD7 monoclonal antibody during tumor process". Doctoral thesis, Lithuanian Academic Libraries Network (LABT), 2011. http://vddb.laba.lt/obj/LT-eLABa-0001:E.02~2011~D_20110309_111259-65000.

Full text

Abstract:

Activation of the immune system during photodynamic therapy (PDT) and improvement of the effector functions of mAbs - these are the ways to use and enhance the potential of the immune system to fight cancer. Tumor cells lack β-glucan as a surface compo¬nent and can‘t trigger complement receptor 3-dependent cellular cytoto¬xicity and initiate tumor-killing activity during PDT. So, it gave rise to the hypothesis that β-glucan in combination with PDT will produce more effective killing of by iC3b fragment opsonized tumor cells. The human Fc portion is essential for the recruiting of human effecto

APA, Harvard, Vancouver, ISO, and other styles

37

Khalili, Boroojeni Parisa. "Evaluation of the effect of trastuzumab (Herceptin) on the development and progression of breast cancer associated skeletal metastasis." Thesis, McGill University, 2007. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=112523.

Full text

Abstract:

Breast cancer is the most commonly diagnosed cancer in women. Despite recent advances in screening and early detection, breast cancer continues to result in a high incidence of morbidity and mortality. In its late stage the majority of patients exhibit signs of destructive skeletal metastasis. This complication is promoted by the production of growth factors by tumor cells which can induce tumor cell proliferation via their interaction with their respective receptors to initiate the vicious cycle of bone resorption. Inhibition of growth factors signaling through their receptors can therefore s

APA, Harvard, Vancouver, ISO, and other styles

38

Hamel, Sophie. "DARPP-32 expression in acquired resistance of breast cancer cells to trastuzumab." Thesis, McGill University, 2007. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=112631.

Full text

Abstract:

Amplification of the receptor tyrosine kinase ErbB-2 has been linked to the proliferation of breast cancer cells.1,2 Trastuzumab targets the extracellular domain of ErbB-2, leading to growth inhibition of approximately 15% of the breast cancers with genomic amplification of the ERBB2 gene.3 Clinical studies have demonstrated its efficacy in both early4 and metastatic breast cancers. 5,6 However, many tumors with ERBB2 amplification are not responsive to treatment.7 Moreover, the ones that initially respond, eventually progress and acquire drug resistance.8 An in vitro model for this acquired r

APA, Harvard, Vancouver, ISO, and other styles

39

Costa, Matthew R. "FC Receptor-Mediated Activities of Env-Specific Monoclonal Antibodies Generated from Human Volunteers Receiving a DNA Prime-Protein Boost HIV Vaccine: A Dissertation." eScholarship@UMMS, 2016. https://escholarship.umassmed.edu/gsbs_diss/866.

Full text

Abstract:

Human immunodeficiency type 1 (HIV-1) is able to elicit broadly potent neutralizing antibodies in a very small subset of individuals only after several years’ infection and as a result, vaccines that elicit these types of antibodies have been difficult to design. The RV144 trial showed that a moderate protection is possible, which may correlate with antibody dependent cellular cytotoxicity (ADCC) activity. Previous studies in the Lu lab demonstrated that in an HIV-1 vaccine phase I trial, DP6-001, a polyvalent Env DNA prime-protein boost formulation, could elicit potent and broadly reactive, g

APA, Harvard, Vancouver, ISO, and other styles

40

Costa, Matthew R. "FC Receptor-Mediated Activities of Env-Specific Monoclonal Antibodies Generated from Human Volunteers Receiving a DNA Prime-Protein Boost HIV Vaccine: A Dissertation." eScholarship@UMMS, 2010. http://escholarship.umassmed.edu/gsbs_diss/866.

Full text

Abstract:

Human immunodeficiency type 1 (HIV-1) is able to elicit broadly potent neutralizing antibodies in a very small subset of individuals only after several years’ infection and as a result, vaccines that elicit these types of antibodies have been difficult to design. The RV144 trial showed that a moderate protection is possible, which may correlate with antibody dependent cellular cytotoxicity (ADCC) activity. Previous studies in the Lu lab demonstrated that in an HIV-1 vaccine phase I trial, DP6-001, a polyvalent Env DNA prime-protein boost formulation, could elicit potent and broadly reactive, g

APA, Harvard, Vancouver, ISO, and other styles

41

Villegas, Vázquez José Adolfo. "Targeting the IL-23/Th17 pathway to treat Myasthenia Gravis." Electronic Thesis or Diss., Sorbonne université, 2019. http://www.theses.fr/2019SORUS393.

Full text

Abstract:

La myasthénie grave (MG) est une maladie auto-immune neuromusculaire due à des autoanticorps dirigés contre les récepteurs à l’acétylcholine. Le thymus MG est inflammatoire. Il possède des centres germinatifs, site de production des auto-anticorps et une surexpression de cytokines favorisant le développement de lymphocytes Th17. Associé à ce cocktail cytokinique, l’IL-23 favorise l’émergence de lymphocytes Th17 délétères. Les objectifs de ma thèse ont été de 1) Déterminer les rôles de la voie IL-23/Th17 dans les évènements thymiques pathogéniques. 2) d’identifier, in vivo, les effets bénéfique

APA, Harvard, Vancouver, ISO, and other styles

42

Savage, Laura Jane. "More than skin deep : detection of subclinical enthesopathy and early psoriatic arthritis in patients with psoriasis in primary and secondary care and assessment of the response to anti-IL-12/IL-23p40 monoclonal antibody skin-directed therapy using ultrasound and whole-body MRI." Thesis, University of Leeds, 2017. http://etheses.whiterose.ac.uk/20543/.

Full text

Abstract:

Objectives: Primary care cohort: To determine the rates of undiagnosed psoriatic arthritis (PsA) amongst patients with psoriasis using clinical examination and screening questionnaires, and test the performance a new PsA screening questionnaire alongside the current standard (Psoriasis Epidemiology Screening Tool, PEST). Secondary care cohort: To develop novel ultrasound and whole body magnetic resonance imaging (WBMRI) protocols to facilitate the comprehensive assessment of subclinical abnormalities within the peripheral and axial skeleton of immunomodulatory therapy-naïve patients with psor

APA, Harvard, Vancouver, ISO, and other styles

43

Albanesi, Marcello. "Receptors, cells & mechanisms responsible for antibody-induced tumor therapy." Paris 6, 2012. http://www.theses.fr/2012PA066553.

Full text

Abstract:

Monoclonal antibodies (mAbs) can be used to specifically target tumor cells over-expressing specific antigens. In most of the cases, the binding of the mAbs on the target antigen enables via the Fc portion of mAbs the recruitment of phagocytic and/or cytotoxic immune cells bearing receptors for the Fc portion of IgG (FcγR). Several FcRs exist that differ from each other for both their functional activity and expression pattern among immune cells. Moreover, numerous differences exist between mouse and human FcRs. However, which of the different FcγRs and which cell population is required for

APA, Harvard, Vancouver, ISO, and other styles

44

Ashok, Mahima. "Analysis of HER2 testing in breast cancer." Diss., Atlanta, Ga. : Georgia Institute of Technology, 2009. http://hdl.handle.net/1853/29711.

Full text

Abstract:

Thesis (Ph.D)--Biomedical Engineering, Georgia Institute of Technology, 2010.<br>Committee Chair: Griffin, Paul; Committee Member: Butera, Robert; Committee Member: Halpern, Michael; Committee Member: Nichols, Richard; Committee Member: Vidakovic, Brani. Part of the SMARTech Electronic Thesis and Dissertation Collection.

APA, Harvard, Vancouver, ISO, and other styles

45

LAIRES, Raquel de Sá da Silva. "Trypanosoma brucei peptidase inhibitors.Immunolocalization, secretion and potential use as targets for therapy." Doctoral thesis, Instituto de Higiene e Medicina Tropical, 2013. http://hdl.handle.net/10362/19282.

Full text

Abstract:

As peptidases encontram-se envolvidas em diversas funções biológicas possuindo um papel importante na patogenicidade de várias infecções parasitárias. Em mamíferos, a actividade peptidica é controlada por inibidores endógenos, como as cistatinas e as serpinas. Os genes que codificam para inibidores homólogos às cistatinas e serpinas de mamíferos, encontram-se ausentes do genoma de tripanossomatídeos. A ecotina é uma proteína de Escherichia coli, capaz de inibir uma grande variedade de peptidases serínicas da família S1A, tais como a tripsina. Existem duas proteínas do tipo da ecotina em T. bru

APA, Harvard, Vancouver, ISO, and other styles

46

Chakraborti, Srinjoy. "Therapeutic Antibody Against Neisseria gonorrhoeae Lipooligosaccharide, a Phase-variable Virulence Factor." eScholarship@UMMS, 2017. https://escholarship.umassmed.edu/gsbs_diss/905.

Full text

Abstract:

Neisseria gonorrhoeae (Ng) which causes gonorrhea has become multidrug-resistant, necessitating the development of novel therapeutics and vaccines. mAb 2C7 which targets an epitope within an important virulence factor, the lipooligosaccharide (LOS), is a candidate therapeutic mAb. Ninety-four percent of clinical isolates express the 2C7-epitope which is also a vaccine target. Ng expresses multiple LOS(s) due to phase-variation (pv) of LOS glycosyltransferase (lgt) genes. mAb 2C7 reactivity requires a lactose extension from the LOS core Heptose (Hep) II (i.e. lgtG ‘ON’ [G+]). Pv results in HepI

APA, Harvard, Vancouver, ISO, and other styles

47

Chakraborti, Srinjoy. "Therapeutic Antibody Against Neisseria gonorrhoeae Lipooligosaccharide, a Phase-variable Virulence Factor." eScholarship@UMMS, 2005. http://escholarship.umassmed.edu/gsbs_diss/905.

Full text

Abstract:

Neisseria gonorrhoeae (Ng) which causes gonorrhea has become multidrug-resistant, necessitating the development of novel therapeutics and vaccines. mAb 2C7 which targets an epitope within an important virulence factor, the lipooligosaccharide (LOS), is a candidate therapeutic mAb. Ninety-four percent of clinical isolates express the 2C7-epitope which is also a vaccine target. Ng expresses multiple LOS(s) due to phase-variation (pv) of LOS glycosyltransferase (lgt) genes. mAb 2C7 reactivity requires a lactose extension from the LOS core Heptose (Hep) II (i.e. lgtG ‘ON’ [G+]). Pv results in HepI

APA, Harvard, Vancouver, ISO, and other styles

48

Lafon, Monique. "La nucleocapside du virus rabique : une nouvelle cible pour la reponse immunitaire et pour la therapie." Paris 7, 1987. http://www.theses.fr/1987PA077219.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Edwards, Aaron David. "Production of functionality enhanced monoclonal antibodies via gene therapy." Thesis, 2014. https://hdl.handle.net/2144/15370.

Full text

Abstract:

While the last century of medical discoveries has made a significant impact on improving the lives of human populations across the globe, a perfect solution to the yearly infection cycle from the influenza virus has yet to be discovered. Although vaccines stand the best chance at targeting yearly epidemics, new treatment options must be created to combat the arrival of rapidly mutating and antiviral-resistant strains of the virus that could lead to another pandemic such as the 1918 Spanish flu that killed millions worldwide. We describe a method to create functionally enhanced monoclonal antib

APA, Harvard, Vancouver, ISO, and other styles

50

Focà, Annalia. "Monoclonal antibodies as powerful tools in diagnosis and therapy." Tesi di dottorato, 2015. http://www.fedoa.unina.it/10273/1/Foc%C3%A0%20Annalia%202015.pdf.

Full text

Abstract:

STUDY I Nodal is a potent embryonic morphogen belonging to the TGF-beta superfamily. Typically, it binds to the Alk4/ActRIIB receptor complex in the presence of the co-receptor Cripto-1. Nodal expression is physiologically restricted to embryonic tissues and human embryonic stem cells and is absent in normal cells, including melanocytes. However it re-emerges in a number of human cancers, including melanoma, breast and colon cancer. Recent studies indicate that Nodal expression correlates with melanoma tumor progression toward a metastatic phenotype, indeed inhibition of the Nodal path

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!